CVS Health announced earlier this week that it is taking action to combat high drug spending in a new comprehensive program aimed at helping patients save money on medications.
CVS Health announced earlier this week that it is taking action to combat high drug spending in a new comprehensive program aimed at helping patients save money on medications.
Through this initiative, CVS Health is launching a new tool called the CVS Pharmacy Rx Savings Finder. The tool will allow the company’s retail pharmacists to quickly evaluate individual prescription savings opportunities at the pharmacy counter for the first time.
The tool will show pharmacy teams whether the prescribed medication is on the patient’s formulary and if it’s the most affordable available option. Using the Rx Savings Finder, the pharmacist will also be able to identify whether the patient might be able to save money by filling a 90-day prescription rather than a 30-day prescription.
“Armed with the information available through our Rx Savings Finder, our more than 30,000 CVS pharmacists can play an important role by helping patients save money on their medications, providing advice on how and when to take them, and ultimately helping them achieve better health outcomes,” said Kevin Hourican, executive vice president of retail pharmacy at CVS Pharmacy. “We are beginning this process with our CVS Caremark [pharmacy benefit manager, PBM] members and expect to roll it out more broadly throughout the year.”
In another effort to combat high drug prices, the company’s PBM, CVS Caremark, is also offering its members preventive drug lists that itemize medications for many common chronic conditions that are available with no co-pay. CVS Caremark also provides a real-time benefits program with which, at time of prescribing, providers are able to see member-specific drug costs based on formulary, along with up to 5 of the lowest-cost, clinically appropriate alternatives.
During a pilot program, CVS found that 95% of patients asked to switch drugs to a lower-cost option when given the choice, and 85% of doctors also chose to make such a switch.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Etanercept Biosimilar Switch Shows Stable Outcomes and Disease Control in RA
May 13th 2025Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on clinical scores, ultrasound scans, or lab tests, according to a new study.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.